-
1.发明申请Deuterated Catecholamine Derivatives and Medicaments Comprising Said Compounds 有权氘代儿茶酚胺衍生物和包含所述化合物的药物公开(公告)号：US20090018191A1
公开(公告)日：2009-01-15
申请号：US12224120
申请日：2007-02-16
IPC分类号： A61K31/216 , C07C229/08 , A61P25/00
CPC分类号： C07C229/36 , C07B59/001 , C07B2200/07
摘要： The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically acceptable salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.
摘要翻译： 本发明涉及氘代儿茶酚胺衍生物以及含有这些化合物的药物。 此外，本发明涉及氘代儿茶酚胺衍生物及其生理上可接受的盐以及含有这些化合物的药物组合物，也与酶抑制剂组合用于治疗基于多巴胺缺乏症的疾病或疾病 破坏酪氨酸转运或破坏酪氨酸脱羧酶，以及其他疾病。
-
2.发明授权Deuterated substituted dihydrofuranones and medicaments containing these compounds 失效氘代取代的二氢呋喃酮和含这些化合物的药物公开(公告)号：US07317039B2
公开(公告)日：2008-01-08
申请号：US10498709
申请日：2002-12-11
IPC分类号： A61K31/34 , C07D307/46
CPC分类号： A61K31/365 , C07D307/32
摘要： The invention concerns deuterated substituted dihydrofuranones and pharmaceuticals containing these compounds.In addition, the invention concerns the use of deuterated substituted dihydrofuranones for the treatment of symptoms for the irritating states of degenerative joint disorders, of acute pain and primary dysmenorrhea.In addition, the invention discloses pharmaceutical compositions, which contain deuterated substituted dihydrofuranones as well as their physiologically compatible salts, in addition to pharmaceutically compatible adjuvants and/or additives, for the treatment of symptoms for the irritating states of degenerative joint disorders, of acute pain and primary dysmenorrhea.
摘要翻译： 本发明涉及氘代取代的二氢呋喃酮和含有这些化合物的药物。 此外，本发明涉及氘代取代的二氢呋喃酮用于治疗退行性关节疾病，急性疼痛和原发性痛经的刺激状态的症状的用途。 此外，本发明还公开了药物组合物，除药学上相容的佐剂和/或添加剂之外，还含有氘代取代的二氢呋喃酮及其生理相容的盐，用于治疗急性疼痛的退行性关节疾病的刺激状态的症状 和原发性痛经。
-
3.发明申请Deuterated catecholamine derivatives and medicaments comprising said compounds 有权氘代儿茶酚胺衍生物和包含所述化合物的药物公开(公告)号：US20060135615A1
公开(公告)日：2006-06-22
申请号：US10539845
申请日：2003-12-18
IPC分类号： A61K31/198
CPC分类号： C07C229/36 , C07B59/001
摘要： The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically compatible salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.
摘要翻译： 本发明涉及氘代儿茶酚胺衍生物以及含有这些化合物的药物。 此外，本发明涉及使用氘代儿茶酚胺衍生物及其生理上相容的盐，以及含有这些化合物的药物组合物，也与酶抑制剂组合用于治疗多巴胺缺乏症或基于 破坏酪氨酸转运或破坏酪氨酸脱羧酶，以及其他疾病。
-
4.发明申请Deuterated substituted dihydrofuranones and medicaments containing these compounds 失效氘代取代的二氢呋喃酮和含这些化合物的药物公开(公告)号：US20050176814A1
公开(公告)日：2005-08-11
申请号：US10498709
申请日：2002-12-11
IPC分类号： C07D307/58 , A61K31/365 , A61P15/00 , A61P19/02 , A61P29/00 , A61P43/00 , C07D307/32
CPC分类号： A61K31/365 , C07D307/32
摘要： The invention concerns deuterated substituted dihydrofuranones and pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated substituted dihydrofuranones for the treatment of symptoms for the irritating states of degenerative joint disorders, of acute pain and primary dysmenorrhea. In addition, the invention discloses pharmaceutical compositions, which contain deuterated substituted dihydrofuranones as well as their physiologically compatible salts, in addition to pharmaceutically compatible adjuvants and/or additives, for the treatment of symptoms for the irritating states of degenerative joint disorders, of acute pain and primary dysmenorrhea.
摘要翻译： 本发明涉及氘代取代的二氢呋喃酮和含有这些化合物的药物。 此外，本发明涉及氘代取代的二氢呋喃酮用于治疗退行性关节疾病，急性疼痛和原发性痛经的刺激状态的症状的用途。 此外，本发明还公开了药物组合物，除药学上相容的佐剂和/或添加剂之外，还含有氘代取代的二氢呋喃酮及其生理相容的盐，用于治疗急性疼痛的退行性关节疾病的刺激状态的症状 和原发性痛经。
-
5.发明申请公开(公告)号：US20050069276A1
公开(公告)日：2005-03-31
申请号：US10494914
申请日：2002-11-07
IPC分类号： A61K31/519 , A61P7/02 , A61P9/00 , A61P9/12 , A61P11/00 , A61P11/06 , A61P11/08 , A61P15/00 , A61P15/10 , C07D487/04
CPC分类号： C07D487/04 , C07B2200/05
摘要： The invention concerns deuterated pyrazolopyrimidinones as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated pyrazolopyrimidinones for the inhibition of thrombocyte adhesion and aggregation, for the long-term increase of memory and learning functions, as well as for the treatment of cardiac and circulatory disorders, hypertonia, pulmonary hypertonia, erectile dysfunction and obstructive respiratory disorders such as, e.g., bronchial asthma. In addition, the invention discloses pharmaceutical compositions of deuterated pyrazolopyrimidinones as well as their physiological compatible salts for the inhibition of thrombocyte adhesion and aggregation, for the long-term increase of memory and learning functions, as well as for the treatment of cardiac and circulatory disorders, hypertonia, pulmonary hypertonia, erectile dysfunction and obstructive respiratory disorders such as, e.g., bronchial asthma, in addition to pharmaceutically compatible adjuvants and/or additives.
摘要翻译： 本发明涉及氘代吡唑并嘧啶酮以及含有这些化合物的药物。 此外，本发明涉及氘化吡唑并嘧啶酮用于抑制血小板粘附和聚集的用途，用于记忆和学习功能的长期增加，以及用于治疗心脏和循环系统疾病，高血压，肺高张力，勃起 功能障碍和阻塞性呼吸系统疾病，例如支气管哮喘。 此外，本发明公开了氘化吡唑并嘧啶酮的药物组合物及其生理相容性盐，用于抑制血小板凝血和聚集，长期增加记忆和学习功能，以及治疗心脏和循环障碍 ，高血压，肺性高血压，勃起功能障碍和阻塞性呼吸系统疾病，例如支气管哮喘，以及药学上相容的佐剂和/或添加剂。
-
6.发明申请Addition Salts of Tolperisone, Processes for Their Preparation and Use Thereof 审中-公开添加盐酸托吡酮，其制备方法及用途公开(公告)号：US20090298893A1
公开(公告)日：2009-12-03
申请号：US11886887
申请日：2006-03-21
IPC分类号： A61K31/44 , C07D211/82
CPC分类号： C07D295/108
摘要： Addition salts of 2,4′-dimethyl-3-piperidinopropiophenone (tolperisone) are described, wherein the salt is formed with an acid R—COOH and wherein R is the organic group of a physiologically compatible organic acid. Described also are processes for the preparation of these addition salts, the use thereof for pharmaceutical preparations and pharmaceuticals containing these addition salts.
摘要翻译： 描述了2,4'-二甲基-3-哌啶基苯丙酮（甲苯哌酮）的加成盐，其中该盐由酸性R-COOH形成，并且其中R是生理上相容的有机酸的有机基团。 还描述了这些加成盐的制备方法，其用于药物制剂的用途和含有这些加成盐的药物。
-
公开(公告)号：US06518300B2
公开(公告)日：2003-02-11
申请号：US09973152
申请日：2001-10-09
IPC分类号： A61K31385
CPC分类号： A61K31/385 , Y10S514/824
摘要： Lipid metabolic disorders, such as hyperlipidemia or hyperlipoproteinemia can be treated by administering to an afflicted individual an effective amount of 5-(1,2-dithiolan-3-yl) valeric acid (&agr;-lipoic acid) or one of its physiologically acceptable salts. Pharmaceutical compositions containing (&agr;-lipoic acid) and methods for making such compositions also are disclosed.
-
8.发明授权Deuterated catecholamine derivatives and medicaments comprising said compounds 有权氘代儿茶酚胺衍生物和包含所述化合物的药物公开(公告)号：US08247603B2
公开(公告)日：2012-08-21
申请号：US12224120
申请日：2007-02-16
IPC分类号： C07B59/00 , C07C229/08 , A61P25/00 , A61K31/198
CPC分类号： C07C229/36 , C07B59/001 , C07B2200/07
摘要： The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically acceptable salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.
摘要翻译： 本发明涉及氘代儿茶酚胺衍生物以及含有这些化合物的药物。 此外，本发明涉及氘代儿茶酚胺衍生物及其生理上可接受的盐以及含有这些化合物的药物组合物，也与酶抑制剂组合用于治疗基于多巴胺缺乏症的疾病或疾病 破坏酪氨酸转运或破坏酪氨酸脱羧酶，以及其他疾病。
-
9.发明授权Deuterated catecholamine derivatives and medicaments comprising said compounds 有权氘代儿茶酚胺衍生物和包含所述化合物的药物公开(公告)号：US08168820B2
公开(公告)日：2012-05-01
申请号：US10539845
申请日：2003-12-18
IPC分类号： C07B59/00 , C07C229/08 , A61P25/00 , A61K31/198
CPC分类号： C07C229/36 , C07B59/001
摘要： The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically compatible salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.
摘要翻译： 本发明涉及氘代儿茶酚胺衍生物以及含有这些化合物的药物。 此外，本发明涉及使用氘代儿茶酚胺衍生物及其生理上相容的盐，以及含有这些化合物的药物组合物，也与酶抑制剂组合用于治疗多巴胺缺乏症或基于 破坏酪氨酸转运或破坏酪氨酸脱羧酶，以及其他疾病。
-
10.发明申请Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases 审中-公开使用1-多巴，其衍生物和包含所述化合物的药物用于预防精神病公开(公告)号：US20070082953A1
公开(公告)日：2007-04-12
申请号：US10539793
申请日：2003-12-18
IPC分类号： A61K31/198 , A61K31/137
CPC分类号： A61K31/198 , A61K31/137 , A61K45/06 , A61K2300/00
摘要： The present invention concerns the use of L-dopa, its derivatives or physiologically compatible salts thereof for the prophylaxis of psychotic disorders and for the treatment of diseases which are caused by disrupted tyrosine transport or disrupted tyrosine decarboxylase. In addition, the invention concerns pharmaceutical compositions which contain L-dopa, its derivatives or physiologically compatible salts thereof for the prophylaxis of psychotic disorders, in addition to pharmaceutically compatible adjuvants and additives. In addition, the invention concerns the combination of L-dopa, its derivatives or physiologically compatible salts thereof with enzyme inhibitors for the prophylaxis of psychotic disorders and for the treatment of disorders which are caused by disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as corresponding pharmaceutical compositions for the prophylaxis of psychotic disorders and for the treatment of diseases which are caused by disrupted tyrosine transport or disrupted tyrosine decarboxylase.
摘要翻译： 本发明涉及L-多巴，其衍生物或其生理上相容的盐用于预防精神病和用于治疗由酪氨酸转运或酪氨酸脱羧酶破坏引起的疾病的用途。 此外，本发明还涉及除了药学上相容的佐剂和添加剂之外，还含有用于预防精神病的L-多巴，其衍生物或其生理上相容的盐的药物组合物。 此外，本发明涉及左旋多巴，其衍生物或其生理上相容的盐与酶抑制剂的组合，用于预防精神病和用于治疗由酪氨酸转运或破坏的酪氨酸脱羧酶引起的病症，以及 用于预防精神病和用于治疗由酪氨酸转运或酪氨酸脱羧酶破坏引起的疾病的相应药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.012 秒)
